Four-week complete healing rate fails to show statistical significance compared to placebo group.
Company to review future development strategy following full clinical data analysis.
HLB Therapeutics announced that its neurotrophic keratitis (NK) drug candidate, RGN-259, failed to meet its primary endpoint in a U.S. Phase 3 clinical trial.
On the 16th, HLB Therapeutics released the topline results of the Phase 3 trial (SEER-2) for RGN-259, which was conducted by its U.S. subsidiary, ReGenTree.
The company received the topline results regarding the primary endpoint from the contract research organization (CRO) managing the trial on the 13th.
According to the findings, there was no statistically significant difference in the complete healing rate at four weeks post-administration between the RGN-259 treatment group and the placebo group.
HLB Therapeutics previously failed to secure statistical significance for the primary endpoint in a European Phase 3 trial (SEER-3) last June. Since then, the company had bolstered expectations for the U.S. trial by refining patient selection and operational strategies. During an investor relations (IR) session in October, the company had set a goal of engaging with the U.S. Food and Drug Administration (FDA) in the second quarter of 2027 and securing a global licensing deal with a major pharmaceutical firm in the third quarter, contingent on the success of the U.S. trial. However, the primary endpoint was not met in this study either.
HLB Therapeutics expects to receive the full clinical trial data from the CRO within the coming weeks. The company plans to conduct a thorough analysis of the clinical results, including detailed findings on the primary endpoint, secondary endpoints, and treatment responses across subgroups.
Ahn Ki-hong, CEO of HLB Therapeutics, stated, "While we did not secure statistical significance for the primary endpoint in these topline results, we intend to comprehensively review detailed findings related to therapeutic efficacy by closely analyzing the full clinical data." He added, "Based on these results, we will carefully evaluate our future development direction and plans, and will pursue necessary follow-up measures promptly and responsibly."







